BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Bristol-Myers Squibb (BMS) and Celgene have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.

BMS and Celgene merge to create premier innovative biopharma company

The transaction will create a leading focused specialty biopharma company well positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. With complementary areas of focus, the combined company will operate with global reach and scale, maintaining the speed and agility that is core to each company’s strategic approach.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” said Giovanni Caforio, Chairman and CEO of BMS. “As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation. We will also benefit from an expanded early- and late-stage pipeline that includes six expected near-term product launches. Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.”

Dr Caforio continued: “We are impressed by what Celgene has accomplished for patients, and we look forward to welcoming Celgene employees to BMS. Our new company will continue the strong patient focus that is core to both companies’ missions, creating a shared organization with a goal of discovering, developing and delivering innovative medicines for patients with serious diseases. We are confident we will drive value for shareholders and create opportunities for employees.”

“For more than 30 years, Celgene’s commitment to leading innovation has allowed us to deliver life-changing treatments to patients in areas of high unmet need. Combining with BMS, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company,” said Mark Alles, Chairman and CEO of Celgene. “Our employees should be incredibly proud of what we have accomplished together and excited for the opportunities ahead of us as we join with BMS, where we can further advance our mission for patients. We look forward to working with the BMS team as we bring our two companies together.”

Strategic benefits

  • Leading franchises with complementary product portfolios provide enhanced scale and balance. The combination creates:
    • Leading oncology franchises in both solid tumors and hematologic malignancies led by Opdivo and Yervoy as well as Revlimid and Pomalyst
    • A top five immunology and inflammation franchise led by Orencia and Otezla
    • The #1 cardiovascular franchise led by Eliquis.
    • The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and inflammation and cardiovascular disease.

  • Near-term launch opportunities representing greater than $15 billion in revenue potential. The combined company will have six expected near-term product launches:
    • Two in immunology and inflammation, TYK2 and ozanimod
    • Four in hematology, luspatercept, liso-cel (JCAR017), bb2121 and fedratinib.
    • These launches leverage the combined commercial capabilities of the two companies and will broaden and enhance Bristol-Myers Squibb’s market position with innovative and differentiated products. This is in addition to a significant number of lifecycle management registrational readouts expected in Immuno-Oncology (IO).

  • Early-stage pipeline builds sustainable platform for growth. The combined company will have a deep and diverse early-stage pipeline across solid tumors and hematologic malignancies, immunology and inflammation, cardiovascular disease and fibrotic disease leveraging combined strengths in innovation. The early-stage pipeline includes 50 high potential assets, many with important data readouts in the near-term. With a significantly enhanced early-stage pipeline, BMS will be well positioned for long-term growth and significant value creation.
  • Powerful combined discovery capabilities with world-class expertise in a broad range of modalities. Together, the Company will have expanded innovation capabilities in small molecule design, biologics/synthetic biologics, protein homeostasis, antibody engineering and cell therapy. Furthermore, strong external partnerships provide access to additional modalities.
  • Read More

    Related news

    An increased risk of a hard or ‘no deal Brexit?

    An increased risk of a hard or ‘no deal Brexit?

    24 Dec 2018

    A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

    Read more 
    One month on: medical cannabis is still taboo despite change in law

    One month on: medical cannabis is still taboo despite change in law

    11 Dec 2018

    Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

    Read more 
    EU FMD - time is running out!

    EU FMD - time is running out!

    13 Nov 2018

    Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

    Read more 
    Proprietary nasal delivery formulation of diazepam reaches NDA

    Proprietary nasal delivery formulation of diazepam reaches NDA

    7 Nov 2018

    The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

    Read more 
    DSCSA one-month countdown!

    DSCSA one-month countdown!

    30 Oct 2018

    With only a month to go, it really is too late to start trying to develop an in-house solution.

    Read more 
    Global pharma set for strong year

    Global pharma set for strong year

    23 Oct 2018

    Eight of the top ten pharma nations reporting improving market conditions.

    Read more 
    Generics companies to move away from little white pills

    Generics companies to move away from "little white pills"

    14 Oct 2018

    Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

    Read more 
    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    9 Oct 2018

    Therapeutic ADC market expected to reach $4 billion by 2023.

    Read more 
    Movement on the market reflected at CPhI Worldwide 2018

    Movement on the market reflected at CPhI Worldwide 2018

    3 Oct 2018

    Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

    Read more 
    Sanofi to refocus two global business units

    Sanofi to refocus two global business units

    19 Sep 2018

    The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

    Read more